Journal
Who Actually Makes Your GLP-1
Six parties get collapsed into one phrase, and only one of them holds the record that matters.
Six parties get collapsed into one phrase, and only one of them holds the record that matters. This piece sets out what is established on which pharmacy makes compounded semaglutide, which record holds it, and what remains unverified — with the underlying figures published as tables and charts so the reasoning is checkable rather than asserted.
Key findings
- Six parties get collapsed into one phrase, and only one of them holds the record that matters.
- Every figure here is drawn from a dated capture or an FDA primary source.
- Regulatory framework and entity-specific claims are held to different evidence standards.
- Open fields render as explicit statuses, never as estimates.
- No provider pays for coverage or placement on this platform.
| Topic | which pharmacy makes compounded semaglutide |
|---|---|
| Category | Verification |
| Pricing captured | 2026-07-06 |
| Framework sources | FDA, verified 2026-07-23 |
| Provider relationship | No Public Evidence Found no financial relationship exists |
Six parties, one phrase
Provider, prescriber, 503A pharmacy, 503B facility, state board, FDA — all routinely collapsed into 'the pharmacy'. They hold different licences and appear in different registers.
A provider's own credentials are close to irrelevant to product quality. The record that matters belongs to the dispensing pharmacy, and the provider is the party who can name it.
The three registers that answer most questions
State board of pharmacy: holds the licence, the permitted scope of compounding, and disciplinary orders. This is the only system covering 503A pharmacies, which is most of them.
FDA's registered outsourcing facility list: covers 503B facilities only, and now publishes inspection dates, whether a Form 483 was issued, and the action status.
FDA warning letter database: the agency's stated positions, and the closeout record that determines whether one is current.
| # | Provider | Total / month | Format | Notes |
|---|---|---|---|---|
| 1 | NexLife | $147 | Injectable | Microdose, 12-month ($1,764). M2M $189. No membership, flat at every covered dose. Below every dose studied in |
| 2 | Found | $169 | Injectable | 12-month prepaid. Medication included, flat at all doses. |
| 3 | Enhance.MD | $169 | Injectable | Microdose 1 mg/week. Delivery every 12 weeks. |
| 4 | NexLife | $186 | Injectable | Standard injection, 12-month ($2,232). M2M $215. No membership, flat at every covered dose. |
| 5 | Shed | $199 | Injectable | Microdose programme. 2-month minimum. |
| 6 | Oak Longevity | $199 | Injectable | Flat across dosages, no subscription. |
| 7 | NexLife | $199 | Oral / ODT | ODT, 12-month ($2,388). M2M $229. No trial evidence for this dosage form. |
| 8 | Shed | $229 | Sublingual | GLP-1 liquid drops. 2-month minimum. |
| 9 | Shed | $245 | Injectable | 12-month prepaid. Increases at higher doses. |
| 10 | Mochi Health | $278 | Injectable | Membership required. |
The question that resolves the most
Which pharmacy dispenses, by exact legal name and state licence number. It is checkable in minutes against a public register, it cannot be fabricated without leaving a trace, and a refusal to answer before payment is itself the finding.
Registration and inspections are facility specific. Facilities under common ownership and control are inspected individually. Before purchasing, FDA advises determining that the specific facility in which the drugs are compounded is an outsourcing facility with a satisfactory inspection. FDA
Chart data as a table
| FL | 16 |
|---|---|
| TX | 16 |
| NJ | 10 |
| CA | 7 |
| PA | 5 |
| CO | 4 |
| MO | 3 |
| AZ | 3 |
| AR | 3 |
| OH | 3 |
What no register will tell you?
Whether the specific vial you received contains what the label says. Concentration accuracy, sterility assurance and identity are properties of a preparation, not of an entity, and no public record covers them.
That is the irreducible gap in compounded supply, and it is why FDA recommends an approved product where one is available and appropriate.
What would change this analysis?
Three things would. A final determination on the 503B bulks list proposal, which the closed docket now makes likely within months. A change in the approved-product pricing that has repriced the category — the $149 oral tier is recent and competitive pressure has been moving it. And any published pharmacokinetic work on compounded preparations, which would move several questions here from unmeasured to measured.
None of those is speculative. Each has a named decision-maker and, in two cases, a live process. This page carries its own date so the gap between what was checked and what is current stays visible.
How to check any of this yourself
Regulatory framework: FDA's compounding pages carry the statutory position and the declaratory orders that ended the shortage exception. Every framework claim on this platform links to one of them.
Facility status: FDA's registered outsourcing facility list is updated weekly and now publishes inspection dates, whether a Form 483 was issued, and the action status. State licensure sits with the relevant board of pharmacy — a different register, and the only one covering 503A pharmacies.
Pricing: every figure here is a dated capture against the provider's own published page, computed as a total. The full dataset is published as JSON and CSV so the arithmetic can be rerun.
Applying this to which pharmacy makes compounded semaglutide
Six parties get collapsed into one phrase, and only one of them holds the record that matters.
Everything above is checkable against a named public record. Where this platform has not performed that check, the field renders as an explicit status rather than an inferred value — which tells you precisely what to go and confirm.
What this means
- Regulatory framework and dates are cited to FDA primary sources.
- Pricing figures are dated captures against provider pages, computed as totals.
- Every open field carries an explicit status rather than an estimate.
What this does not mean
- That any named entity is compliant, safe, or non-compliant.
- That a lower price indicates better evidence or quality.
- That this platform certifies or endorses any facility or preparation.
- Pricing captured 2026-07-06; confirm at checkout before relying on it.
- Regulatory positions change through rulemaking, guidance and enforcement action.
- Entity-specific licence and enforcement records are covered on the monitoring pages, not here.
- Nothing here is legal or medical advice.
Frequently asked questions
What is the short answer on which pharmacy makes compounded semaglutide?
Six parties get collapsed into one phrase, and only one of them holds the record that matters.
Where do these figures come from?
Pricing from dated captures against provider pages (2026-07-06); regulatory facts from FDA primary sources.
Does any provider pay to appear here?
No. This platform has no affiliate, referral, sponsorship, or financial relationship with any provider.
How often is this updated?
When the underlying capture or regulatory position changes. Every page carries its own date.
Is this legal or medical advice?
No. It reports what named public records say on the dates they were checked. Clinical decisions belong with a prescriber and legal questions with a qualified adviser.
How can I check the figures myself?
The pricing dataset is published as JSON and CSV, the FDA register and inspection records are linked on every page that uses them, and each figure carries its capture date.
What if a record here is wrong?
Report it through the corrections process. Named entities can also respond through the right-to-respond route, and accepted corrections are logged with their date.
Sources
- GLP-1 pricing database
- FDA — Registered Outsourcing Facilities
- FDA — Information for Outsourcing Facilities
- FDA — Q&A: Outsourcing Facility Registration
Update history
| Date | Change |
|---|---|
| 2026-07-23 | Record published at current snapshot. |
Dates change only for substantive updates. Entities may submit a correction or response through the right-to-respond process.